research use only

Seladelpar PPAR agonist

Name: Seladelpar
Brand: Selleck Chemicals
SKU: S6635
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S6635

Seladelpar(MBX-8025) is a potent and selective agonist of peroxisome proliferator–activated receptor-delta (PPAR-δ) with EC50 of 2 nM for human PPAR-δ. MBX-8025 enhances insulin sensitivity, counters dyslipidemia, and reduces hepatic storage of lipotoxic lipids, thereby ameliorating NASH pathology in obese diabetic mice.

Chemical Structure

Molecular Weight: 444.47

Jump to

Quality Control

Batch: Purity: 99.55%

99.55

Related Targets	Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase Vitamin Carbohydrate Metabolism Mitochondrial Metabolism Casein Kinase
Other PPAR Inhibitors	T0070907 GW9662 GW6471 WY-14643 (Pirinixic Acid) GSK3787 GW0742 AZ6102 Harmine Palmitoylethanolamide Astaxanthin

Solubility

In vitro
Batch:

DMSO : 89 mg/mL (200.23 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 89 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	444.47	Formula	C₂₁H₂₃F₃O₅S	Storage (From the date of receipt)	2 years -20°C liquid
CAS No.	851528-79-5	Download SDF		Storage (From the date of receipt)	2 years -20°C liquid

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC₅₀/Ki	PPAR-δ 2 nM(EC50)
References	[1] https://pubmed.ncbi.nlm.nih.gov/29404484/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-11)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06051617	RECRUITING	Primary Biliary Cholangitis	Gilead Sciences	2023-09-07	PHASE3
NCT03301506	ACTIVE_NOT_RECRUITING	Primary Biliary Cirrhosis	Gilead Sciences	2017-12-12	PHASE3
NCT07305363	NOT_YET_RECRUITING	Liver Transplant; Complications; Ischemic Cholangiopathy	University of California, San Diego	2026-05	PHASE2
NCT06060665	COMPLETED	Primary Biliary Cholangitis	Gilead Sciences	2023-09-05	PHASE3
NCT04950764	COMPLETED	Primary Biliary Cholangitis; Compensated Cirrhosis; Hepatic Impairment	Gilead Sciences	2021-11-16	PHASE1
NCT04620733	COMPLETED	Primary Biliary Cholangitis	Gilead Sciences	2021-04-21	PHASE3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):